Pfizer (PFE) Stock
Global pharmaceutical company producing medicines and vaccines. Here's the price, business snapshot, and what's worth knowing about Pfizer in July 2026.
Pfizer Inc (PFE) is a large-cap global pharmaceutical company known for developing, producing and commercialising medicines and vaccines across areas such as oncology, immunology, rare disease and infectious disease. The company’s scale, diversified portfolio and R&D pipeline are key considerations for investors: revenue is driven by established products, new approvals and licensing or royalty arrangements. Important risks include regulatory decisions, patent expiries, pricing pressure, competition and litigation — all of which can materially affect earnings. Pfizer has historically returned capital to shareholders via dividends and buybacks, but dividend levels and capital allocation depend on cash flow and strategic priorities. For those researching the stock, focus on upcoming clinical readouts, regulatory milestones, patent timelines, and quarterly financials. This is general educational information, not personal advice; pharmaceutical stocks can be volatile and past performance is not a reliable indicator of future results.
Why It’s Moving
Pfizer trades on mixed analyst views as investors wait for a clearer earnings catalyst.
- Analyst sentiment on Pfizer remains mixed, with some forecasts leaning Buy while others still cluster around Hold, suggesting investors are waiting for a clearer catalyst before re-rating the stock.
- The spread in price targets is wide, which points to uncertainty over the pace of Pfizer’s recovery and how quickly earnings can stabilize after recent pressure.
- With no major company-specific headlines in the last week, the stock appears to be moving more on broader expectations for pharma fundamentals, pipeline execution, and valuation than on any fresh event.
Pfizer trades on mixed analyst views as investors wait for a clearer earnings catalyst.
- Analyst sentiment on Pfizer remains mixed, with some forecasts leaning Buy while others still cluster around Hold, suggesting investors are waiting for a clearer catalyst before re-rating the stock.
- The spread in price targets is wide, which points to uncertainty over the pace of Pfizer’s recovery and how quickly earnings can stabilize after recent pressure.
- With no major company-specific headlines in the last week, the stock appears to be moving more on broader expectations for pharma fundamentals, pipeline execution, and valuation than on any fresh event.
When is the next earnings date for Pfizer (PFE)?
Pfizer’s next earnings date is expected on August 4, 2026, although one source lists July 29, 2026 and the company has not formally confirmed a date. The most consistently cited timing is August 4, 2026, and the report would cover Q2 2026. For investor briefing purposes, the earnings event is therefore best treated as an early-August release.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Pfizer's stock as is, with a target price of $29.54 indicating potential growth.
Financial Health
Pfizer is generating strong revenue and profits, demonstrating solid cash flow and financial stability.
Dividend
Pfizer's high dividend yield of 6.96% is appealing for those seeking dividend income. If you invested $1000 you would be paid $69.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring PFE
AI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketUS Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketFed Division: Fortress Balance Sheets Explained
The Federal Reserve is showing a rare public division on whether to raise, lower, or hold interest rates, creating uncertainty for the markets. This theme focuses on investing in companies with strong financial health that are better equipped to handle the market volatility resulting from unpredictable monetary policy.
Published: 19 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketFlight to Safety Assets | Fed Uncertainty Overview
A landmark Supreme Court case is set to determine whether the president can fire a Federal Reserve governor, placing the central bank's political independence at a critical juncture. This event could spur market volatility, potentially benefiting safe-haven assets and defensive stocks that investors turn to in times of uncertainty.
Published: 21 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline and innovation
Clinical readouts and regulatory approvals can shift expectations quickly, so investors often watch the pipeline closely — though outcomes can be uncertain.
Key revenue drivers
Vaccines, blockbusters and royalty agreements drive sales, but patent cliffs and pricing pressures can affect future revenue.
Global market reach
Pfizer operates worldwide with diverse market exposure, which can smooth regional volatility but also creates regulatory and geopolitical risks.
Compare Pfizer with other stocks
Pfizer vs Moderna
Pfizer vs Moderna: A Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
